Karbicombi (Candesartan/Hydrochlorothiazide)

Karbicombi is a combination pharmaceutical product containing Candesartan cilexetil and Hydrochlorothiazide, primarily used for the treatment of essential hypertension. The brand is managed by Krka, d. d., Novo mesto, a prominent international generic pharmaceutical company. Manufacturing operations for Karbicombi are carried out across several of Krka's production sites in Europe, primarily in Slovenia.

Krka was established in the mid-20th century in Slovenia and has grown to become one of the top generic pharmaceutical companies in the world. The brand represents a significant part of Krka's cardiovascular portfolio, reflecting the company's focus on providing affordable therapeutic options for chronic conditions. As an independent entity, Krka remains the ultimate owner and operator of the brand and its global distribution networks.